DNA methylation in urological malignancies (review)

International Journal of Oncology

Volumn 13, Issue 1, 1998, Pages 151-167

  Schulz, Wolfgang A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

DNA methylation; Urological malignancies

Indexed keywords

AZACITIDINE; CYTOSINE; DNA; DNA METHYLTRANSFERASE; NUCLEOSIDE ANALOG; PROTEIN P53; S ADENOSYLMETHIONINE; SOMATOMEDIN B; THYMIDINE;

ARTICLE; DNA METHYLATION; GENE MUTATION; HUMAN; NEPHROBLASTOMA; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; TESTIS TUMOR; TUMOR SUPPRESSOR GENE; URINARY TRACT CANCER;

EID: 0031805802     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.1.151     Document Type: Article

References (308)

1. Feinberg AP and Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301: 89-92, 1983.
2. Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW and Ehrlich M: The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res 11: 6883-6894, 1983.
3. Jones PA: The role of DNA methylation in cancer. Adv Cancer Res 54: 1-23, 1990.
4. Laird PW and Jaenisch R: DNA methylation and cancer. Hum Mol Genet 3: 1487-1495, 1994.
5. Counts JL and Goodman JI: Alterations in DNA methylation may play a variety of roles in carcinogenesis. Cell 83: 13-15, 1995.
6. Laird PW: The role of DNA methylation in cancer genetics and epigenetics. Annu Rev Genet 30:441-464, 1996.
7. Szyf M: The DNA methylation machinery as a target for anticancer therapy. Pharmacol Ther 70: 1-37, 1996.
8. Versteeg R: Aberrant methylation in cancer. Am J Hum Genet 60: 751-754, 1997.
9. Baylin SB, Herman JG, Graff JR, Vertino PM and Issa JP: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72: 141-196, 1998.
10. Razin A and Kafri T: DNA methylation from embryo to adult. Prog Nucleic Acid Res Mol Biol 48: 53-81, 1994.
11. Monk M, Boubelik M and Lehnert S: Temporal and regional changes in DNA methylation in the embryonic, extraembryonic and germ cell lineages during mouse embryo development. Development 99: 371-382, 1987.
12. Trasler JM, Hake LE, Johnson PA, Alcivar AA, Millette CF and Hecht NB: DNA methylation and demethylation events during meiotic prophase in the mouse testis. Mol Cell Biol 10: 1828-1834, 1990.
13. Ariel M, McCarrey J and Cedar H: Methylation patterns of testis-specific genes. Proc Natl Acad Sci USA 88: 2317-2321, 1991.
14. Howlett SK and Reik W: Methylation levels of maternal and paternal genomes during preimplantation development. Development 113: 119-127, 1991.
15. Monk M: Genomic imprinting. Genes Dev 2: 921-925, 1988.
16. Gold JD and Pedersen RA: Mechanisms of genomic imprinting in mammals. Curr Top Dev Biol 29: 227-280, 1994.
17. Razin A and Cedar H: DNA methylation and genomic imprinting. Cell 77: 473-476, 1994.
18. Barlow DP: Gametic imprinting in mammals. Science 270: 1610-1613, 1995.
19. Lalande M: Parental imprinting and human disease. Annu Rev Genet 30: 173-195, 1996.
20. Nakao M and Sasaki H: Genomic imprinting: significance in development and diseases and the molecular mechanisms. J Biochem 120: 467-473, 1996.
21. Tycko B: DNA methylation in genomic imprinting. Mutat Res 386: 131-140, 1997.
22. Razin A and Cedar H: DNA methylation and embryogenesis. In: DNA Methylation: Molecular Biology and Biological Significance. Jost JP and Saluz HP (eds). Birkhäuser, Basel, pp343-357, 1993.
23. Ghazi H, Gonzales FA and Jones PA: Methylation of CpG-island-containing genes in human sperm, fetal and adult tissues. Gene 114: 203-210, 1992.
24. Antequera F and Bird A: CpG islands. In: DNA Methylation: Molecular Biology and Biological Significance. Jost JP and Saluz HP (eds). Birkhäuser, Basel, pp169-185, 1993.
25. Teubner B and Schulz WA: Exemption of satellite DNA from demethylation in immortalized differentiated derivatives of F9 mouse embryonal carcinoma cells. Exp Cell Res 210: 192-200, 1994.
26. Miller OJ, Schnedl W, Allen J and Erlanger BF: 5-methylcytosine localised in mammalian constitutive heterochromatin. Nature 251: 636-637, 1974.
27. Sentis C, Ludena P and Fernandez-Piqueras J: Non-uniform distribution of methylatable CCGG sequences on human chromosomes as shown by in situ methylation. Chromosoma 102: 267-271, 1993.
28. Montpellier C, Bourgeois CA, Kokalj-Vokac N, Muleris M, Niveleau A, Reynaud C, Gibaud A, Malfoy B and Dutrillaux B: Detection of methylcytosine-rich heterochromatin on banded chromosomes. Cancer Genet Cytogenet 78: 87-93, 1994.
29. Turker MS and Bestor TH: Formation of methylation patterns in the mammalian genome. Mutat Res 386: 119-130, 1997.
30. Jost JP and Bruhat A: The formation of DNA methylation patterns and the silencing of genes. Prog Nucleic Acid Res Mol Biol 57: 217-248, 1997.
31. Li E, Bestor TH and Jaenisch R: Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69: 915-926, 1992.
32. Yen RWC, Vertino PM, Nelkin BD, Yu JJ, El-Deiry W, Cumaraswamy A, Lennon GG, Trask BJ, Celano P and Baylin SB: Isolation and characterization of the cDNA encoding human DNA methyltransferase. Nucleic Acids Res 20: 2287-2291, 1992.
33. Bestor TH, Laudano A, Mattaliano R and Ingram V: Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. J Mol Biol 203: 971-983, 1988.
34. Tajima S, Studa H, Wakabayashi N, Asano A, Mizuno S and Nishimori K: Isolation and expression of a chicken DNA methyltransferase cDNA. J Biochem 117: 1050-1057, 1995.
35. Noyer-Weidner M and Trautner TA: Methylation of DNA in procaryotes. In: DNA Methylation: Molecular Biology and Biological Significance. Jost JP and Saluz HP (eds). Birkhäuser, Basel, pp39-108, 1993.
36. Tucker KL, Beard C, Dausman J, Jackson-Grusby L, Laird PW, Lei H, Li E and Jaenisch R: Germ-line passage is required for establishment of methylation and expression patterns of imprinted but not of nonimprinted genes. Genes Dev 10: 1008-1020, 1996.
37. Tucker KL, Talbot D, Lee MA, Leonhardt H and Jaenisch R: Complementation of methylation deficiency in embryonic stem cells by a DNA methyltransferase minigene. Proc Natl Acad Sci USA 93: 12920-12925, 1996.
38. Yoder JA, Yen RWC, Vertino PM, Bestor TH and Baylin SB: New 5' regions of the murine and human genes for DNA (cytosine-5)-methyltransferase. J Biol Chem 271: 31092-31097, 1996.
39. Yoder JA, Somans NS, Verdine GL and Bestor TH: DNA (cytosine-S)-methyltransferases in mouse cells and tissues. Studies with a mechanism-based probe. J Mol Biol 270: 385-395, 1997.
40. Cross SH, Meehan RR, Nan X and Bird A: A component of the transcriptional repressor MeCP1 shares a motif with DNA methyltransferase and HRX proteins. Nat Genet 16: 256-259, 1997.
41. Glickman JF, Pavlovich JG and Reich NO: Peptide mapping of the murine DNA methyltransferase reveals a major phosphorylation site and the start of translation. J Biol Chem 272: 17851-17857, 1997.
42. Tollefsbol TO and Hutchison CA: Control of methylation spreading in synthetic DNA sequences by the murine DNA methyltransferase. J Mol Biol 269: 494-504, 1997.
43. Zimmermann C, Guhl E and Graessmann A: Mouse DNA methyltransferase (MTase) deletion mutants that retain the catalytic domain display neither de novo nor maintenance methylation activity in vivo. Biol Chem 378: 393-405, 1997.
44. Leonhardt H, Page AW, Weier HU and Bestor TH: A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei. Cell 71: 865-873, 1992.
45. Chuang LSH, Ian HI, Koh TW, Ng HH, Xu G and Li BFL: Human DNA-(cytosine-S) methyltransferase-PCNA complex as a target for p21 (WAF1). Science 277: 1996-2000, 1997.
46. Bestor TH: Activation of mammalian DNA methyltransferase by cleavage of a Zn binding regulatory domain. EMBO J 11: 2611-2617, 1992.
47. Teubner B and Schulz WA: Regulation of DNA methyltransferase during differentiation of F9 embryonal carcinoma cells. J Cell Physiol 165: 284-290, 1995.
48. Liu Y, Sun L and Jost JP: In differentiating mouse myoblasts DNA methyltransferase is posttranscriptionally and posttranslationally regulated. Nucleic Acids Res 24: 2718-2722, 1996.
49. Lei H, Oh SP, Okano M, Jüttermann R, Goss KA, Jaenisch R and Li E: De novo DNA cytosine methyltransferase activities in mouse embryonic stem cells. Development 122: 3195-3205, 1996.
50. Malagnac F, Wendel B, Goyon C, Faugeron G, Zickler D, Rossignol JL, Noyer-Weidner M, Vollmayr P, Trautner TA and Walter J: A gene essential for de novo methylation and development in Ascobolus reveals a novel type of eukaryotic DNA methyltransferase structure. Cell 91: 281-290, 1997.
51. Yoder JA and Bestor TH: A candidate mammalian DNA methyltransferase related to pmt1p of fission yeast. Hum Mol Genet 7: 279-284, 1998.
52. Frank D, Lichtenstein M, Paroush Z, Bergman Y, Shani M, Razin A and Cedar H: Demethylation of genes in animal cells. Philos Trans R Soc Lond B 326: 241-252, 1990.
53. Jost JP and Jost YC: Transient DNA demethylation in differentiating mouse myoblasts correlates with higher activity of 5-methyldeoxycytidine excision repair. J Biol Chem 269: 10040-10043, 1994.
54. Frank D, Keshet I, Shani M, Levine A, Razin A and Cedar H: Demethylation of CpG islands in embryonic cells. Nature 351: 239-241, 1991.
55. Jost JP, Siegmann M, Sun L and Leung R: Mechanisms of DNA demethylation in chicken embryos. J Biol Chem 270: 9734-9739, 1995.
56. Szyf M, Theberge J and Bozovic V: Ras induces a general DNA demethylation activity in mouse embryonal P19 cells. J Biol Chem 270: 12690-12696, 1995.
57. Weiss A, Keshet I, Razin A and Cedar H: DNA demethylation in vitro: involvement of RNA. Cell 86: 709-718, 1996.
58. Frémont M, Siegmann M, Gaulis S, Matthies R, Hess D and Jost JP: Demethylation of DNA by purified chick embryo 5-methylcytosine-DNA glycosylase requires both protein and RNA. Nucleic Acids Res 25: 2375-2380, 1997.
59. Jost JP, Frémont M, Siegmann M and Hofsteenge J: The RNA moiety of chick embryo 5-methylcytosine-DNA glycosylase targets DNA demethylation. Nucleic Acids Res 25: 4545-4550, 1997.
60. Monk M, Adams RLP and Rinaldi A: Decrease in DNA methylase activity during preimplantation development in the mouse. Development 112: 189-192, 1991.
61. Benoit G and Trasler JM: Developmental expression of DNA methyltransferase messenger ribonucleic acid, protein, and enzyme activity in the mouse testis. Biol Reprod 50: 1312-1319, 1994.
62. Goto K, Numata M, Komura JI, Ono T, Bestor TH and Kondo H: Expression of DNA methyltransferase gene in mature and immature neurons as well as proliferating cells in mice. Differentiation 56: 39-44, 1994.
63. Trasler JM, Trasler DG, Bestor TH, Li E and Ghibu F: DNA methyltransferase in normal and DNMTn/DNMTn mouse embryos. Dev Dyn 206: 239-247, 1996.
64. Mertineit C, Yoder JA, Taketo T, Laird DW, Trasler JM and Bestor TH: Sex-specific exons control DNA methyltransferase in mammalian germ cells. Development 125: 889-897, 1998.
65. Bestor TH and Tycko B: Creation of genomic methylation patterns. Nat Genet 12: 363-367, 1996.
66. Szyf M: DNA methylation patterns: an additional level of information? Biochem Cell Biol 69: 764-767, 1991.
67. Hasse A and Schulz WA: Enhancement of reporter gene de novo methylation by fragments from the α-fetoprotein control region. J Biol Chem 269: 1821-1826, 1994.
68. Magewu AN and Jones PA: Ubiquitous and tenacious methylation of the CpG site in codon 248 of the p53 gene may explain its frequent appearance as a mutational hot spot in human cancer. Mol Cell Biol 14: 4225-4232, 1994.
69. Mummaneni P, Walker KA, Bishop PL and Turker MS: Induction of epigenetic gene inactivation by a mammalian methylation center. J Biol Chem 270: 788-792, 1995.
70. Hasse A, Schulz WA and Sies H: De novo methylation of transfected CAT gene plasmid constructs in F9 mouse embryonal carcinoma cells. Biochim Biophys Acta 1131: 16-22, 1992.
71. Brandeis M, Frank D, Keshet I, Siegfried Z, Mendelsohn M, Nemes A, Temper V, Razin A and Cedar H: Sp1 elements protect a CpG island from de novo methylation. Nature 371: 435-438, 1994.
72. MacLeod D, Charlton J, Mullins J and Bird A: SpI binding sites in the mouse aprt gene promoter arc required to prevent methylation of the CpG island. Genes Dev 8: 2282-2292, 1994.
73. Doerfler W: Patterns of DNA methylation-evolutionary vestiges of foreign DNA inactivation as a host defense mechanism. Biol Chem Hoppe-Seyler 372: 557-564, 1991.
74. Yoder JA, Walsh CP and Bestor TH: Cytosine methylation and the ecology of intragenomic parasites. Trends Genet 13: 335-340, 1997.
75. Singer MJ, Marcotte BA and Selker EU: DNA methylation associated with repeat-induced point mutation in Neurospora crassa. Mol Cell Biol 15: 5586-5597, 1995.
76. Chen X, Santhana Mariappan SV, Catasti P, Ratliff R, Moyzis RK, Laayoun A, Smith SS, Bradbury EM and Gupta G: Hairpins are formed by the single DNA strands of the fragile X triplet repeats: structure and biological implications. Proc Natl Acad Sci USA 92: 5199-5203, 1995.
77. Godde JS, Kass SU, Hirst MC and Wolffe AP: Nucleosome assembly on methylated CGG triplet repeats in the fragile X mental retardation gene 1 promoter. J Biol Chem 271: 24325-24328, 1996.
78. Englcr P, Haasch D, Pinkert CA, Doglio L, Glymour M, Brinster R and Storb U: A strain-specific modifier on mouse chromosome 4 controls the methylation of independent transgene loci. Cell 65: 939-947, 1991.
79. Weng A, Magnuson T and Storb U: Strain-specific transgene methylation occurs early in mouse development and can be recapitulated in embryonic stem cells. Development 121: 2853-2859, 1995.
80. Cheng NC, Chan AJK, Beitsma MM, Speleman F, Westerveld A and Versteeg R: A human modifier of methylation for class I HLA genes (MEMO-1) maps to chromosomal bands 1p35-36.1. Hum Mol Genet 5: 309-317, 1996.
81. Singer-Sam J and Riggs AD: X chromosome inactivation and DNA methylation. In: DNA Methylation: Molecular Biology and Biological Significance. Jost JP and Saluz HP (eds). Birkhäuser, Basel, pp358-384, 1993.
82. Doerfler W: DNA methylation and gene activity. Annu Rev Biochem 51: 93-124, 1983.
83. Ehrlich M and Ehrlich KC: Effect of DNA methylation on the binding of vertebrate and plant proteins to DNA. In: DNA Methylation: Molecular Biology and Biological Significance. Jost JP and Saluz HP (eds). Birkhäuser, Basel, pp145-168, 1993.
84. Graessmann M and Graessmann A: DNA methylation, chromatin structure and the regulation of gene expression. In: DNA Methylation: Molecular Biology and Biological Significance. Jost JP and Saluz HP (eds). Birkhäuser, Basel, pp404-424, 1993.
85. Tate PH and Bird AP: Effects of DNA methylation on DNA-binding proteins and gene expression. Curr Opin Genet Dev 3: 226-231, 1993.
86. Khan R, Zhang XY, Supakar PC, Ehrlich KC and Ehrlich M: Human methylated DNA-binding protein: determinants of a pBR322 recognition site. J Biol Chem 263: 14374-14383, 1988.
87. Meehan RR, Lewis JD, McKay S, Kleiner EL and Bird AP: Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs. Cell 58:499-507, 1989.
88. Lewis JD, Meehan RR, Henzel WJ, Maurer-Fogy I, Jeppesen P, Klein F and Bird A: Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 69: 905-914, 1992.
89. Nan X, Campoy FJ and Bird A: MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88: 471-481, 1997.
90. McArthur M and Thomas JO: A preference of histone H1 for methylated DNA. EMBO J 15: 1705-1714, 1996.
91. Hsieh CL and Lieber MR: CpG methylated minichromosomes become inaccessible for V(D)J recombination after undergoing replication. EMBO J 11: 315-325, 1992.
92. Goodhardt M, Cavelier P, Doyen N, Kallenbach S, Babinet C and Rougeon F: Methylation status of immunoglobulin χ gene segments correlates with their recombination potential. Eur J Immunol 23: 1789-1795, 1993.
93. La Salle JM and Lalande M: Homologous association of oppositely imprinted chromosomal domains. Science 272: 725-728, 1996.
94. Hernandez R, Frady A, Zhang XY, Varela M and Ehrlich M: Preferential induction of chromosome 1 multibranched figures and whole-arm deletions in a human pro-B cell line treated with 5-azacytidine or 5-azadeoxycytidine. Cytogenet Cell Genet 76: 196-201, 1997.
95. Miniou P, Bourc'his D, Molina-Gomes D, Jeanpierre M and Viegas-Péquignot E: Undermethylation of Alu sequences in ICF syndrome: molecular and in situ analysis. Cytogenet Cell Genet 77: 308-313, 1997.
96. Miniou P, Jeanpierre M, Bourc'his D, Coutinho Barbosa AC, Blanquet V and Viegas-Péquignot E: α-satellite DNA methylation in normal individuals and in ICF patients: heterogeneous methylation of constitutive heterochromatin in adult and fetal tissues. Hum Genet 99: 738-745, 1997.
97. Leteurtre F, Kohlhagen G, Fesen MR, Tanizawa A, Kohn KW and Pommier Y: Effects of DNA methylation on topoisomerase I and II cleavage activities. J Biol Chem 269: 7893-7900, 1994.
98. Stopper H, Eckert I, Wagener P and Schulz WA: Formation of micronuclei and inhibition of topoisomerase II in the comet assay in mammalian cells with altered DNA methylation. Recent Res Cancer Res 143: 183-193, 1996.
99. Jiricny J: Mismatch repair and cancer. Cancer Surv 28: 47-68, 1996.
100. Tolberg ME, Fundcrburk SJ, Klisak I and Smith SS: Structural organization and DNA methylation patterning within the mouse L1 family. J Biol Chem 262: 11167-11175, 1987.
101. Jürgens B, Schmitz-Dräger BJ and Schulz WA: Hypomethylation of L1 LINE sequences prevailing in human urothelial carcinoma. Cancer Res 56: 5698-5703, 1996.
102. Löwer R, Löwer J and Kurth R: The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Proc Natl Acad Sci USA 93: 5177-5184, 1996.
103. Tönjes RR, Loewer R, Boiler K, Donner J, Hasenmaier B, Kirsch H, Konig H, Korbmacher C, Limbach C, Lugert R, Phelps RC, Scherer J, Thelen K, Loewer J and Kurth R: HERV-K: the biologically most active human endogenous retrovirus family. J AIDS Hum Retrovirol 13 (Suppl 1): 261-267, 1996.
104. Woodcock DM, Lawler CB, Linsenmeyer ME, Doherty JP and Warren WD: Asymmetric methylation in the hypermethylated CpG promoter region of the human L1 retrotransposon. J Biol Chem 272: 7810-7816, 1997.
105. Löwer R, Boller K, Hasenmaier B, Korbmacher C, Müller-Lantzsch N, Löwer J and Kurth R: Identification of human endogenous retroviruses with complex mRNA expression and particle formation. Proc Natl Acad Sci USA 90: 4480-4484, 1993.
106. Rubin CM, van de Voort CA, Teplitz RL and Schmid CW: Alu repeated DNAs are differentially methylated in primate germ cells. Nucleic Acids Res 22: 5121-5127, 1994.
107. Goodchild NL, Freeman D and Mager DL: Spliced HERV-H endogenous retroviral sequences in human genomic DNA: evidence for amplification via retrotransposition. Virology 206: 164-173, 1995.
108. Schulte AM, Lai S, Kurtz A, Czubayko F, Riegel AT and Wellstein A: Human trophoblast and choriocarcinoma expression of the growth factor pleiotrophin attributable to germ-line insertion of an endogenous retrovirus. Proc Natl Acad Sci USA 93: 14759-14764, 1996.
109. Dombroski BA, Mathias SL, Nanthakumar E, Scott AF and Kazazian HH: Isolation of an active human transposable element. Science 254: 1805-1808, 1991.
110. Miki Y, Nishisho I, Horii A, Miyoshi Y, Utsunomiya J, Kinzler KW, Vogelstein B and Nakamura Y: Disruption of the APC gene by a retrotransposal insertion of L1 sequence in a colon cancer. Cancer Res 52: 643-645, 1992.
111. Dombroski BA, Scott AF and Kazazian HH: Two additional potential retrotransposons isolated from a human Ll subfamily that contains an active retrotransposable element. Proc Natl Acad Sci USA 90: 6513-6517, 1993.
112. Schmutte C, Baffa R, Veronese LM, Murakumo Y and Fishel R: Human thymine-DNA glycosylase maps at chromosome 12p22-q24.1: a region of high loss of heterozygosity in gastric cancer. Cancer Res 57: 3010-3015, 1997.
113. Bird AP: DNA methylation and the frequency of CpG in animal DNA. Nucleic Acids Res 8: 1499-1504, 1980.
114. Bird AP: CpG-rich islands and the function of DNA methylation. Nature 321: 209-213, 1987.
115. Rideout WM, Coetzee GA, Olumi AF and Jones PA: 5-methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 249: 1288-1290, 1990.
116. Jones PA, Rideout WM, Shen JC, Spruck CH and Tsai YC: Methylation, mutation and cancer. Bioessays 14: 33-36, 1992.
117. Tornaletti S and Pfeifer GP: Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers. Oncogene 10: 1493-1499, 1995.
118. Goelz SE, Vogelstein B, Hamilton SR and Feinberg AP: Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 228: 187-190, 1985.
119. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM and Bos JL: Genetic alterations during colorectal tumor development. N End J Med 319: 525-532, 1988.
120. Bedford MT and van Helden PD: Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res 47: 5274-5276, 1987.
121. Cravo M, Pinto R, Fidalgo P, Chaves P, Gloria L, Nobre-Leitao C and Costa Mira F: Global DNA hypomethylation occurs in the early stages of intestinal type gastric carcinoma. Gut 39: 434-438, 1996.
122. Bernardino J, Roux C, Almeida A, Vogt N, Gibaud A, Gerbault-Seureau M, Magdelenat H, Bourgeois CA, Malfoy B and Dutrillaux B: DNA hypomethylation in breast cancer: an independent parameter of tumor progression? Cancer Genet Cytogenet 97: 83-89, 1997.
123. Bianchi NO, Bianchi MS, Alitalo K and De La Chapelle A: The methylation pattern of normal and truncated amplified human c-myc oncogenes. Biochim Biophys Acta 1007: 350-355, 1989.
124. Del Senno L, Maestri I, Piva R, Hanau S, Reggiani A, Romano A and Russo G: Differential hypomethylation of the c-Myc protooncogene in bladder cancers at different stages and grades. J Urol 142: 146-149, 1989.
125. Dante R, Dante-Paire J, Rigal D and Roizes G: Methylation patterns of long interspersed repeated DNA and alphoid repetitive DNA from human cell lines and tumors. Anticancer Res 12:559-564, 1992.
126. Kim YI, Giuliano A, Hatch KD, Schneider A, Nour MA, Dallai GE, Selhub J and Mason JB: Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma. Cancer 74: 893-899, 1994.
127. Lombardi B and Smith ML: Tumorigenesis, protooncogene activation, and other gene abnormalities in methyl deficiency. J Nutr Biochem 5: 2-9, 1994.
128. Alves G, Tatro A and Fanning T: Differential methylation of human LINE-1 retrotransposons in malignant cells. Gene 176: 39-44, 1996.
129. De Bustros A, Nelkin BD, Silverman A, Ehrlich G, Poiesz B and Baylin SB: The short arm of chromosome 11 is a 'hot spot' for hypermethylation in human neoplasia. Proc Natl Acad Sci USA 85: 5693-5697, 1988.
130. Silverman AL, Park JG, Hamilton SR, Gazdar AF, Luk GD and Baylin SB: Abnormal methylation of the calcitonin gene in human colonie neoplasms. Cancer Res 49: 3468-3473, 1989.
131. Greger V, Passarge E, Hopping W, Messmer E and Horsthemke B: Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet 83: 155-158, 1989.
132. Shiraishi M and Sekiya T: Change in methylation status of DNA of remaining allele in human lung cancers with loss of heterozygosity on chromosomes 3p and 13q. Jpn J Cancer Res 80: 924-927, 1989.
133. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM and Dryja TP: Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 48: 880-888, 1991.
134. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DSR, Gnarra JR, Linehan WM and Baylin SB: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91: 9700-9704, 1994.
135. Zion M, Ben-Yehuda D, Avraham A, Cohen O, Wetzler M, Melloul D and Ben-Neriah Y: Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc Natl Acad Sci USA 91: 10722-10726, 1994.
136. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE and Baylin SB: E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55: 5195-5199, 1995.
137. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB and Sidransky D: 5'CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692, 1995.
138. INK4 protein induction by 5-aza 2'-deoxycytidine. Oncogene 11: 1211-1216, 1995.
139. Wales MM, Biel MA, El-Deiry W, Nelkin BD, Issa JP, Cavenee WK, Kuerbitz SJ and Baylin SB: p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med 1: 570-577, 1995.
140. Fueyo J, Gomez-Manzano C, Bruner JM, Saito Y, Zhang B, Zhang W, Levin VA, Yung WKA and Kyritsis AP: Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene 13: 1615-1619, 1996.
141. Dobrovic A and Simpfendorfer D: Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 57: 3347-3350, 1997.
142. Graff JR, Herman JG, Myöhänen S, Baylin SB and Vertino PM: Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem 272: 22322-22329, 1997.
143. Herman JG, Civin CI, Issa JPJ, Collector MI, Sharkis SJ and Baylin SB: Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57: 837-841, 1997.
144. Prowse AH, Webster AR, Richards FM, Richard S, Olschwang S, Resche F, Affara NA and Maher ER: Somatic inactivation of the VHL gene in von Hippel-Lindau disease. Am J Hum Genet 60: 765-771, 1997.
145. Stirzaker C, Millar DS, Paul CL, Warnecke PM, Harrison J, Vincent PC, Frommer M and Clark SJ: Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. Cancer Res 57: 229-237, 1997.
146. Cosgrove DE and Cox GS: Effects of sodium butyrate and 5-azacytidine on DNA methylation in human tumor cell lines: variable response to drug treatment and withdrawal. Biochim Biophys Acta 1087: 80-86, 1990.
147. Ferguson T, Lapidus RG, Baylin SB and Davidson NE: Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 55: 2279-2283, 1995.
148. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, van Tornout JM and Jones PA: Methylation of the 5'CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55: 4531-4535, 1995.
149. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D and Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530, 1995.
150. Makos M, Nelkin BD, Chazin VR, Cavenee WK, Brodeur GM and Baylin SB: DNA hypermethylation is associated with 17p loss in neural tumors. Cancer Res 53: 2715-2718, 1993.
151. Makos M, Nelkin BD, Reiter RE, Gnarra JR, Brooks J, Isaacs W, Linehan M and Baylin SB: Regional DNA hypermethylation at D17.5 precedes 17p structural changes in the progression of renal tumors. Cancer Res 53: 2719-2722, 1993.
152. Ribieras S, Song-Wang XG, Martin V, Lointier P, Frappart L and Dante R: Human breast and colon cancers exhibit alterations of DNA methylation patterns at several DNA segments on chromosomes 11p and 17p. J Cell Biochcm 56: 86-96, 1994.
153. Li E, Beard C and Jaenisch R: Role for DNA methylation in genomic imprinting. Nature 366: 362-365, 1993.
154. Matsuoka S, Thompson JS, Edwards MC, Barletta JM, Grundy P, Kalikin LM, Harper JW, Elledge SJ and Feinberg AP: Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. Proc Natl Acad Sci USA 93: 3026-3030, 1996.
155. Chung WY, Yuan L, Feng L, Hensle T and Tycko B: Chromosome 11p15.5 regional imprinting: comparative analysis of KIP2 and H19 in human tissues and Wilms' tumors. Hum Mol Genet 5: 1101-1108, 1996.
156. MacDonald HR and Wevrick R: The necdin gene ist deleted in Prader-Wili syndrome and is imprinted in human and mouse. Hum Mol Genet 6: 1873-1878, 1997.
157. Reik W and Surani MA: Genomic imprinting and embryonal tumours. Cancer Res 338: 112-113, 1989.
158. Sapienza C: Genome imprinting and carcinogenesis. Biochim Biophys Acta 1072: 51-61, 1991.
159. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE and Feinberg AP: Relaxation of imprinted genes in human cancer. Nature 362: 747-755, 1993.
160. Moulton T, Grenshaw T, Hao Y, Moosikasuwan J, Lin N, Dembitzer F, Hensle T, Weiss L, McMorrow L, Loew T, Kraus W, Gerald W and Tycko B: Epigenetic lesions at the H19 locus in Wilms' tumour patients. Nat Genet 7: 440-447, 1994.
161. Rainier S and Feinberg AP: Genomic imprinting, DNA methylation, and cancer. J Natl Cancer Inst 86: 753-759, 1994.
162. Barletta JM, Rainier S and Feinberg AP: Reversal of loss of imprinting in tumor cells by 5-aza-2'-deocycytidine. Cancer Res 57: 48-50, 1997.
163. Joyce JA, Lam WK, Catchpoolc DJ, Jenks P, Reik W, Maher ER and Schofield PN: Imprinting of IGF2 and H19: lack of reciprocity in sporadic Beckwith-Wiedemann syndrome. Hum Mol Genet 6: 1543-1548, 1997.
164. Issa JPJ, Vcrtino PM, Boehm CD, Newsham IF and Baylin SB: Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc Natl Acad Sci USA 93: 11757-11762, 1996.
165. Huff V, Amos CI, Douglass EC, Fisher R, Geiser CF, Krill CE, Li FP, Strong LC and MacDonald JM: Evidence for genetic heterogeneity in familial Wilms' tumor. Cancer Res 57: 1859-1859, 1997.
166. Wen JG, van Steenbrugge GJ, Egeler RM and Nijman RM: Progress of fundamental research in Wilms' tumor. Urol Res 25: 223-230, 1997.
167. Charles AK, Mall S, Watson J and Berry PJ: Expression of the Wilms' tumour gene WT1 in the developing human and in paediatric renal tumours: an immunohistochemical study. Mol Pathol 50: 138-144, 1997.
168. Hiltunen MO, Koistinaho J, Alhonen L, Myöhänen S, Marin S, Kosma VM, Pääkkönen M and Jänne J: Hypermethylation of the WT1 and calcitonin gene promoter regions at chromosome lip in human colorectal cancer. Br J Cancer 76: 1124-1130, 1997.
169. Williams JC, Maitland NJ, Mott MG and Brown KW: Methylation of chromosome 1 Ip genes in Wilms' tumour and kidney tissue. Int J Oncol 1: 743-746, 1992.
170. Ogawa O, Becroft DM, Morison IM, Eccles MR, Skeen JE, Mauger DC and Reeve AE: Constitutional relaxation of insulinlike growth factor II gene imprinting associated with Wilms' tumour and gigantism. Nat Genet 5: 408-412, 1993.
171. Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA, Smith PJ and Reeve AE: Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 362: 749-751, 1993.
172. Moulton T, Chung WY, Yuan L, Hensle T, Waber P, Nisen P and Tycko B: Genomic imprinting and Wilms' tumor. Med Pediatr Oncol 27: 476-483, 1996.
173. Okamoto K, Morison IM, Taniguchi T and Reeve AE: Epigenetic changes at the insulin-like growth factor II/H19 locus in developing kidney is an early event in Wilms tumorigenesis. Proc Natl Acad Sci USA 94: 5367-5371, 1997.
174. Steenman MJC, Rainier S, Dobry CJ, Grundy P, Horon IL and Feinberg AP: Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat Genet 7: 433-439, 1994.
175. Taniguchi T, Sullivan MJ, Ogawa O and Reeve AE: Epigenetic changes encompassing the IGF2/H19 locus associated with relaxation of IGF2 imprinting and silencing of H19 in Wilms tumor. Proc Natl Acad Sci USA 92: 2159-2163, 1995.
176. Pfeifer K and Tilghman SM: Allele-specific gene expression in mammals: the curious case of the imprinted RNAs. Genes Dev 8: 1867-1874, 1994.
177. Weksberg R, Shen DR, Fei YL, Song QL and Squire J: Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome. Nat Genet 5: 143-149, 1993.
178. Catchpoole D, Lam WW, Valler D, Temple IK, Joyce JA, Reik W, Schofield PN and Maher ER: Epigenetic modification and uniparental inheritance of H19 in Beckwith-Wiedemann syndrome. J Med Genet 34: 353-359, 1997.
179. Lee MP, De Baun M, Randhawa G, Reichard BA, Elledge S and Feinberg AP: Low frequency of p57KIP2 mutation in Beckwith-Wiedemann syndrome. Am J Hum Genet 61: 304-309, 1997.
180. O'Keefe D, Dao D, Zhao L, Sanderson R, Warburton D, Weiss L, Anyane-Yeboa K and Tycko B: Coding mutations in p57KIP2 are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms tumors. Am J Hum
181. KIP2 and its reduced expression in Wilms' tumors. Hum Mol Genet 5: 783-788, 1996.
182. Caron H, van Sluis P, van Hoeve M, De Kraker J, Bras J, Slater R, Mannens M, Voute PA, Westerveld A and Versteeg R: Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification. Nat Genet 4: 187-190, 1993.
183. Jost CA, Marin MC and Kaelin WG: P73 is a human p53-rclated protein that can induce apoptosis. Nature 389: 191-194, 1997.
184. Schmidt B, Ackermann R and Strohmeyer T: Molecular biology of testicular germ cell tumors: current status. J Mol Med 73: 355-367, 1995.
185. Peltomäki P: DNA methylation changes in human testicular cancer. Biochim Biophys Acta 1096: 187-196, 1991.
186. Gillis AJ, Verkerk AJ, Dekker MC, van Gurp RJ, Oosterhuis JW and Looijenga LH: Methylation similarities of two CpG sites within exon 5 of human H19 between normal tissues and testicular germ cell tumours of adolescents and adults, without correlation with allelic and total level of expression. Br J Cancer 76: 725-733, 1997.
187. Arima T, Matsuda T, Takagi N and Wake N: Association of IGF2 and H19 imprinting with choriocarcinoma development. Cancer Genet Cytogenet 93: 39-47, 1997.
188. INK4(MTS1) gene inactivation in testicular germ cell tumors. Am J Pathol 151: 859-865, 1997.
189. Knowles MA: Molecular genetics of bladder cancer. Br J Urol 75 (Suppl 1): 57-66, 1995.
190. Bender CM and Jones PA: Molecular genetics in carcinoma of the bladder. In: Carcinoma of the Bladder: Innovations in Management. Petrovich K (ed). Springer (In press).
191. Keen AJ and Knowles MA: Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene 9: 2083-2088, 1994.
192. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D and Sidransky D: Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11: 210-212, 1995.
193. Gonzalez-Zulueta M, Shibata A, Ohneseit PF, Spruck CH, Busch C, Shamaa M, Elbaz M, Nichols PW, Gonzalgo ML, Mamström PU and Jones PA: High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder. J Natl Cancer Inst 87: 1383-1393, 1995.
194. Balázs M, Carroll P, Kerschmann R, Sauter G and Waldmann FM: Frequent homozygous deletion of cyclindependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization. Genes Chromosom Cancer 19: 84-89, 1997.
195. Jarrard DF, Bova GS, Ewing CM, Pin SS, Nguyen SH, Baylin SB, Cairns P, Sidransky D, Herman JG and Isaacs WB: Deletional, mutational, and methylation analyses of CDKN2 (p16/MTSI) in primary and metastatic prostate cancer. Genes Chromosom Cancer 19: 90-96, 1997.
196. INK4A transcript. Cancer Res 55: 2995-2997, 1995.
197. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G and Kamb A: Complex structure and regulation of the P16 (MTSI) locus. Cancer Res 55: 2988-2994, 1995.
198. ARF. Proc Natl Acad Sci USA 94: 669-673, 1997.
199. ARF. Cell 91: 649-659, 1997.
200. Simoneau AR, Spruck CH, Gonzalez-Zulueta M, Gonzalgo ML, Chan MF, Tsai YC, Dean M, Steven K, Horn T and Jones PA: Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations. Cancer Res 56: 5039-5043, 1996.
201. Habuchi T, Luscombe M, Elder PA and Knowles MA: Structure and methylation-based silencing of a gene within a candidate bladder cancer tumor suppressor region at 9q32-33. Genomics (In press).
202. Gonzalgo ML, Liang G, Spruck CH, Zingg JM, Rideout W and Jones PA: Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. Cancer Res 57: 594-599, 1997.
203. Ariel I, Lustig O, Schneider T, Pizov G, Saprir M, De Groot N and Hochberg A: The imprinted H19 gene as a tumor marker in bladder carcinoma. Urology 45: 335-338, 1995.
204. Cooper MJ, Fischer M, Komitowski D, Shevelev A, Schulze E, Ariel I, Tycocinski ML, Miron S, Ilan J, De Groot N and Hochberg A: Developmentally imprinted genes as markers for bladder tumor progression. J Urol 155: 2120-2127, 1996.
205. Sardi I, Dal Canto M, Bartoletti R and Montali E: Abnormal c-myc oncogene DNA methylation in human bladder cancer: possible role in tumor progression. Eur Urol 31: 224-230, 1997.
206. Lipponen PK: Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. J Pathol 175: 203-210, 1995.
207. Schmitz-Dräger BJ, Schulz WA, Jürgens B, Gerharz CD, van Roeyen CRC, Bültel H, Ebert T and Ackermann R: C-myc in bladder cancer - clinical findings and analysis of mechanism. Urol Res 25 (Suppl 1): 45-49, 1997.
208. Trash-Bingham CA, Salazar H, Freed JJ, Greenberg RE and Tartof KD: Genome alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology. Cancer Res 55: 6189-6195, 1995.
209. Bugert P and Kovacs G: Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis. Am J Pathol 149: 2081-2088, 1996.
210. Van den Berg A and Buys CH: Involvement of multiple loci on chromosome 3 in renal cell cancer development. Genes Chromosom Cancer 19: 59-76, 1997.
211. Gnarra JR, Duan DR, Weng Y, Humphrey JS, Chen DYT, Lee S, Pause A, Dudley CF, Latif F, Kuzmin I, Schmidt L, Duh FM, Stackhouse T, Chen F, Kishada T, Wei MH, Lerman MI, Zbar B, Klausner RD and Linehan WM: Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta 1242: 201-210, 1996.
212. Glavac D, Ravnik-Glavac M, Ovcak Z and Masera A: Genetic changes in the origin and development of renal cell carcinoma (RCC). Pflugers Arch 431: R193-R194, 1996.
213. Holt EH, Vasavada RC, Bander NH, Broadus AE and Philbrick WM: Region-specific methylation of the parathyroid hormone-related peptide gene determines its expression in human renal carcinoma cell lines. J Biol Chem 268: 20639-20645, 1993.
214. Antequera F, Boyes J and Bird A: High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell 62: 503-514, 1990.
215. Nonomura N, Nishimura K, Miki T, Kanno N, Kojima Y, Yokoyama M and Okuyama A: Loss of imprinting of the insulinlike growth factor II gene in renal cell carcinoma. Cancer Res 57: 2575-2577, 1997.
216. Kallioniemi OP and Visakorpi T: Genetic basis and clonal evolution of human prostate cancer. Cancer Res 68: 225-255, 1996.
217. Jarrard DF, Bova GS and Isaacs WB: DNA methylation, molecular genetic, and linkage studies in prostate cancer. Prostate 6 (Suppl): 36-44, 1996.
218. Heston WDW: Gene therapy or fruits and vegetables? A biased perspective on prostatic carcinogenesis and hypothetical approaches to its control. Mol Urol 1: 11-20, 1997.
219. Bookstein R, Bova GS, MacGrogan D, Levy A and Isaacs WB: Tumour-suppressor genes in prostatic oncogenesis: a positional approach. Br J Urol 79: 28-36, 1997.
220. Smith JR, Freije D, Carpten JD, Grönberg H, Xu J, Isaacs SD, Brownstein MJ, Steven G, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Walker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM and Isaacs WB: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274: 1371-1374, 1996.
221. Morton RA, Watkins JJ, Bova GS, Wales MM, Baylin SB and Isaacs WB: Hypermethylation of chromosome 17p locus D17S5 in human prostate tissue. J Urol 156: 512-516, 1996.
222. MacGrogan D, Levy A, Bova GS, Isaacs WB and Bookstein R: Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. Genomics 35: 55-65, 1996.
223. Nelson JB, Lee WH, Nguyen SH, Jarrard DF, Brooks JD, Magnuson SR, Opgenorth TJ, Nelson WG and Bova GS: Methylation of the 5' CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer, Res 57: 35-37, 1997.
224. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB and Nelson WG: Cytidinc methylation of regulatory sequences near the π-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 91: 11733-11737, 1994.
225. Lee WH, Isaacs WB, Bova GS and Nelson WG: CpG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. Cancer Epidemiol Biomarkers Prev 6: 443-450, 1997.
226. Morel F, Schulz WA and Sies H: Gene structure and regulation of expression of human glutathione S-transferases alpha. Biol Chem 375: 641-649, 1994.
227. Xia C, Hu J, Ketterer B and Taylor JB: The organization of the human GSTP1-1 gene promoter and its response to retinoic acid and cellular redox status. Biochem J 313: 155-161, 1996.
228. Klöne A, Weidner U, Hussnätter R, Harris J, Meyer D, Peter S, Ketterer B and Sies H: Decreased expression of the glutathione S-transferases alpha and pi genes in human renal cell carcinoma. Carcinogenesis 11: 2179-2183, 1990.
229. Strohmeyer T, Klöne A, Wagner G, Hartmann M and Sies H: Glutathione S-transferases in human testicular germ cell tumors: changes of expression and activity. J Urol 147: 1424-1428, 1992.
230. Eickelmann P, Ebert T, Warskulat U, Schulz WA and Sies H: Expression of NAD(P)H:quinone oxidoreductase and glutathione S-transferases alpha and pi in human renal cell carcinoma and in kidney cancer-derived cell lines. Carcinogenesis 15: 219-225, 1994.
231. Lengauer C, Kinzler KW and Vogelstein B: Genetic instability in colorectal cancers. Nature 386: 623-627, 1997.
232. Razin A, Levine A, Kafri T, Agostini S, Gomi T and Cantoni GL: : Relationship between transient DNA hypomethylation and erythroid differentiation of murine erythroleukemia cells. Proc Natl Acad Sci USA 85: 9003-9006, 1988.
233. Lengauer C, Kinzler KW and Vogelstein B: DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sci USA 94: 2545-2550, 1996.
234. Vertino PM, Spillare EA, Harris CC and Baylin SB: Altered chromosomal methylation patterns accompany oncogeneinduced transformation of human bronchial epithelial cells. Cancer Res 53: 1684-1689, 1993.
235. Wachsmann JT: DNA methylation and the association between genetic and epigenetic changes: relation to carcinogenesis. Mutat Res 375: 1-8, 1997.
236. Klein CB and Costa M: DNA methylation, heterochromatin and epigenetic carcinogens. Mutat Res 386: 163-180, 1997.
237. Mass MJ and Wang L: Arsenic alters cytosine methylation ' patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat Res 386: 263-277, 1997.
238. Lee YW, Klein CB, Kargacin B, Salnikow K, Kitahara J, Dowjat K; Zhitkovich A, Christie NT and Costa M: Carcinogenic nickel silences gene expression by chromatin condensation and DNA methylation: a new model for epigenetic carcinogens. Mol Cell Bibl 15: 2547-2557, 1995.
239. Moore MM: Relative genotoxic potency of arsenic and its methylated metabolites. Mutat Res 386: 279-290, 1997.
240. Shibata A, Ohneseit PF, Tsai YC, Spruck CH, Nichols PW, Chiang HS, Lai MK and Jones PA: Mutational spectrum in the p53 gene in bladder tumors from the endemic area of black foot disease in Taiwan. Carcinogenesis 15: 1085-1087, 1994.
241. Weitzman SA, Turk PW, Milkowski DH and Kozlowski K: Free radical adducts induce alterations in DNA cytosine methylation. Proc Natl Acad Sci USA 91: 1261-1264, 1994.
242. Gerda S and Weitzman SA: Influence of oxygen radical injury on DNA methylation. Mutat Res 386: 141-152, 1997.
243. Nyce J, Leonard S, Canupp D, Schulz S and Wong S: Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance. Proc Natl Acad Sci USA 90: 2960-2964, 1993.
244. Nyce JW: Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. Mutat Res 386: 153-161, 1997.
245. Lu LJW, Liehr JG, Sirbasku DA, Randerath E and Randerath K: Hypomethylation of DNA in estrogen-induced and dependent hamster kidney tumors. Carcinogenesis 9: 925-929, 1988.
246. Kanduc D, Rossiello MR, Aresta A, Cavazza C, Quagliariello E and Farber E: Transitory DNA hypomethylation during liver cell proliferation induced by a single dose of lead nitrate. Arch Biochem Biophys 286: 212-216, 1991.
247. Counts JL, McClain RM and Goodman JI: Comparison of effect of tumor promoter treatments on DNA methylation status and gene expression in B6C3F1 and C57BL/6 mouse liver and in B6C3F1 mouse liver tumors. Mol Carcinog 18: 97-106, 1997.
248. Counts JL and Goodman JI: Hypomethylation of DNA: an epigenetic mechanism involved in tumor promotion. Mol Carcinog 11: 185-188, 1994.
249. Locker J, Reddy TV and Lombardi B: DNA methylation and hepatocarcinogenesis in rats fed a cholinedevoid diet. Carcinogenesis 7: 1309-1312, 1986.
250. Chandar N, Lombardi B, Schulz WA and Locker J: Analysis of Ras genes and linked viral sequences in rat hepatocarcinogenesis. Am J Pathol 129: 232-241, 1987.
251. Wainfan E, Dizik M, Stender M and Christman JK: Rapid appearance of hypomethylated DNA in livers of rats fed cancerpromoting, methyl-deficient diets. Cancer Res 49: 4094-4097, 1989.
252. Dizik M, Christman JK and Wainfan E: Alterations in expression and methylation of specific genes in livers of rats fed a cancer promoting methyl-deficient diet. Carcinogenesis 12: 1307-1312, 1991.
253. Zapisek WF, Cronin GM, Lyn-Cook BD and Poirier LA: The onset of oncogene hypomethylation in the livers of rats fed methyl-deficient, amino acid-defined diets. Carcinogenesis 13: 1869-1872, 1992.
254. Christman JK, Sheikhnejad G, Dizik M, Abileah S and Wainfan E: Reversibility of changes in nucleic acid methylation and gene expression induced in rat liver by severe dietary methyl deficiency. Carcinogenesis 14: 551-557, 1993.
255. Hsieh LL, Wainfain E, Hoshina S, Dizik M and Weinstein IB: Altered expression of retrovirus-like sequences and cellular oncogenes in mice fed methyl-deficient diets. Cancer Res 49: 3795-3799, 1989.
256. Fortin LJ and Genest J: Measurement of homocysteine in the prediction of arteriosclerosis. Clin Biochem 28: 155-162, 1995.
257. Montalescot G, Ankri A, Chadefaux-Vekemans B, Blacher J, Phillippe F, Drobinski G, Benzidia R, Khamoun P and Thomas D: Plasma homocysteine and the extent of atherosclerosis in patients with coronary artery disease. Int J Cardiol 60: 295-300, 1997.
258. Kautiainen TLK and Jones PA: DNA methyltransferase levels in tumorigenic and nontumorigenic cells in culture. J Biol Chem 261: 1594-1598, 1996.
259. El-Deiry WS, Nelkin BD, Celano P, Yen RWC, Falco JP, Hamilton SR and Baylin SB: High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc Natl Acad Sci USA 88: 3470-3474, 1991.
260. Issa JPJ, Vertino PM, Wu J, Sazawal S, Celano P, Nelkin BD, Hamilton SR and Baylin SB: Increased cytosine DNA-methyltransferase activity during colon cancer progression. J Natl Cancer Inst 85: 1235-1240, 1993.
261. Szyf M, Bozovic V and Tanigawa G: Growth regulation of mouse DNA methyltransferase gene expression. J Biol Chem 266: 10027-10030, 1991.
262. Lee PJ, Washer LL, Law DJ, Boland CR, Horon IL and Feinberg AP: Limited up-regulation of DNA methyltransferase in human colon cancer reflecting increased cell proliferation. Proc Natl Acad Sci USA 93: 10366-10370, 1996.
263. Schmutte C, Yang AS, Nguyen TT, Beart RW and Jones PA: Mechanisms for the involvement of DNA methylation in colon Carcinogenesis. Cancer Res 56: 2375-2381, 1996.
264. Belinsky SA, Nikula KJ, Baylin SB and Issa JPJ: Increased cytosine DNA-methyltransferase activity is target-cell-specific and an early event in lung cancer. Proc Natl Acad Sci USA 93: 4045-4050, 1996.
265. MacLeod AR, Rouleau J and Szyf M: Regulation of DNA methylation by the Ras signaling pathway. J Biol Chem 270: 11327-11337, 1995.
266. Rouleau J, MacLeod AR and Szyf M: Regulation of the DNA methyltransferase by the Ras-AP-1 signaling pathway. J Biol Chem 270: 1595-1601, 1995.
267. Wu J, Issa JP, Herman J, Bassett DE, Nelkin BD and Baylin SB: Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH 3T3 cells. Proc Natl Acad Sci USA 90: 8891-8895, 1993.
268. Vertino PM, Issa JP, Pereira-Smith OM and Baylin SB: Stabilization of DNA methyltransferase levels and CpG island hypermethylation precede SV40-induced immortalization of human fibroblasts. Cell Growth Differ 5: 1395-1402, 1994.
269. Vertin PM, Yen RW, Gao J and Baylin SB: De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5-)-methyltransferase. Mol Cell Biol 16: 4555-4556, 1996.
270. Wu J, Herman JG, Wilson G, Lee RY, Yen RWC, Mabry M, De Bustros A, Nelkin BD and Baylin SB: Expression of prokaryotic HhaI DNA methyltransferase is transforming and lethal to NIH 3T3 cells. Cancer Res 56: 616-622, 1996.
271. Mays-Hoopes L, Chao W, Butcher HC and Huang RCC: Decreased methylation of the major mouse long interspersed repeated DNA during aging and in myeloma cells. Dev Genet 7: 65-73, 1986.
272. Hoal-van Helden EG and van Helden PD: Age-related methylation changes in DNA may reflect the proliferative potential of organs. Mutat Res 219: 263-266, 1989.
273. Mays-Hoopes L: DNA methylation in aging and cancer. J Gerontol 44: 35-56, 1989.
274. Catania J and Fairweather DS: DNA methylation and cellular ageing. Mutat Res 256: 283-293, 1991.
275. Hornsby PJ, Yang L, Raju SG and Cheng CY: Changes in gene expression and DNA methylation in adrenocortical cells senescing in culture. Mutat Res 256: 105-113, 1991.
276. Issa JPJ, Ottaviano Y, Celano P, Hamilton SR, Davidson NE and Baylin SB: Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 7: 536-540, 1994.
277. Schroeder M and Mass MJ: CpG methylation inactivates the transcriptional activity of the promoter of the human p53 tumor suppressor gene. Biochem Biophys Res Commun 235: 403-406, 1997.
278. Levine AJ: P53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
279. Bender CM, Pao MM and Jones PA: Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 58: 95-101, 1998.
280. Gonzalgo ML and Jones PA: Mutagenic and epigenetic effects of DNA methylation. Mutat Res 386: 107-118, 1997.
281. Pogribny IP, Basnakian AG, Miller BJ, Lopatina NG, Poirier LA and James SJ: Breaks in genomic DNA and within the p53 gene are associated with hypomethylation in livers of folate/methyl-deficient rats. Cancer Res 55: 1894-1901, 1995.
282. Jones PA and Gonzalgo ML: Altered DNA methylation and genome instability: a new pathway to cancer? Proc Natl Acad Sci USA 94: 2103-2105, 1997.
283. Morse B, Rotherg PG, South VJ, Spandorfer JM and Astrin SM: Insertional mutagenesis of the myc locus by a LINE-1 sequence in a human breast carcinoma. Nature 355: 87-90, 1988.
284. Nagarajan L, Lange B, Cannizzaro L, Finan J, Nowell PC and Huebner K: Molecular anatomy of a 5q interstitial deletion. Blood 75: 82-87, 1990.
285. Holmes SE, Dombroski BA, Krebs CM, Boehm CD and Kazazian HH: A new retrotransposable human L1 element from the LRE2 locus on chromosome 1q produces a chimaeric insertion. Nat Genet 7: 143-148, 1994.
286. Pomykala HM, Bohlander SK, Broeker PL, Olopade OI and Diaz MO: Breakpoint junctions of chromosome 9p deletions in two human glioma cell lines. Mol Cell Biol 14: 7604-7610, 1994.
287. Liu J, Nau MM, Zucman-Rossi J, Powell JI, Allegra CJ and Wright JJ: LINE-I element insertion at the t(11;22) translocation breakpoint of a desmoplastic small round cell tumor. Genes Chromosom Cancer 18: 232-239, 1997.
288. Feng Q, Moran JV, Kazazian HH and Boeke JD: Human L1 retrotransposon encodes a conserved endonuclease required for retrotransposition. Cell 87: 905-916, 1996.
289. Moran JV, Holmes SE, Naas TP, De Berardinis RJ, Boeke JD and Kazazian HH: High frequency retrotransposition in cultured mammalian cells. Cell 87: 917-927, 1996.
290. Hata K and Sakaki Y: Identification of critical CpG sites for repression of L1 transcription by DNA methylation. Gene 189: 227-234, 1997.
291. Leibold DM, Swergold GD, Singer MF, Thayer RE, Dombroski BA and Fanning TG: Translation of LINE-1 DNA elements in vitro and in human cells. Proc Natl Acad Sci USA 87: 6990-6994, 1990.
292. Patience C, Simpson GR, Colletta AA, Welch HM, Weiss RA and Boyd MT: Human endogenous retrovirus expression and reverse transcriptase activity in the T47D mammary carcinoma cell line. J Virol 70: 2654-2657, 1996.
293. Gotzinger N, Sauter M, Roemer K and Mueller-Lantzsch N: Regulation of human endogenous retrovirus-K Gag expression in teratocarcinoma cell lines and human tumours. J Gen Virol 77: 2983-2990, 1996.
294. Steigerwald SD, Pfeifer GP and Riggs AD: Ligation-mediated PCR improves the sensitivity of methylation analysis by restriction enzymes and detection of specific DNA strand breaks. Nucleic Acids Res 18: 1435-1439, 1990.
295. McGrew MJ and Rosenthal N: Quantitation of genomic methylation using ligation-mediated PCR. Biotechniques 15: 722-729, 1993.
296. Herman JG, Graff JR, Myöhänen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.
297. Gonzalgo ML and Jones PA: Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extenstion (Ms-SNuPE). Nucleic Acids Res 25: 2529-2531, 1997.
298. Kubota T, Das S, Christian SL, Baylin SB, Herman JG and Ledbetter DH: Methylation-specific PCR simplifies imprinting analysis. Nat Genet 16: 16-17, 1997.
299. Xiong Z and Laird PW: COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25: 2532-2534, 1997.
300. Gillessen-Kaesbach G, Gross S, Kaya-Westerloh S, Passarge E and Horsthemke B: DNA methylation base testing of 450 patients suspected of having Prader-Willi syndrome. J Med Genet 32: 88-92, 1995.
301. Griffiths TR and Neal DE: Prognostic markers in bladder cancer. Curr Opin Urol 6: 267-271, 1996.
302. Schulz WA, Jankevicius F, Gerharz CD, Kushima M, van Roeyen C, Bültel H, Göbell P and Schmitz-Dräger BJ: Predictive value of molecular alterations for the prognosis of urothelial carcinoma. Cancer Detect Prev (In press).
303. Jaenisch R, Schnieke A and Harbers K: Treatment of mice with 5-azacytidine efficiently activates silent retroviral genomes in different tissues. Proc Natl Acad Sci USA 82: 1451-1455, 1985.
304. Jüttermann R, Li E and Jaenisch R: Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 91: 11797-11801, 1994.
305. Jackson-Grusby L, Laird PW, Magge SN, Moeller BJ and Jaenisch R: Mutagenicity of 5-aza-2'-deoxycytidine is mediated by mammalian DNA methyltransferase. Proc Natl Acad Sci USA 94: 4681-4685, 1997.
306. Ramchandani S, MacLeod AR, Pinard M, von Hofe E and Szyf M: Inhibition of tumorigenesis by a cytosine-DNA methyltransferase antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 94: 684-689, 1997.
307. Qian M, Chen SH, von Hofe E and Gallo JM: Pharmacokinetics and tissue distribution of a DNA-methyltransferase antisense (MT-AS) oligonucleotide and its catabolites in tumor-bearing nude mice. J Pharmacol Exp Ther 282: 663-670, 1997.
308. Chen F, Kishida T, Duh FM, Renbaum P, Orcutt ML, Schmidt L and Zbar B: Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res 55: 4804-4807, 1995.